Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 6:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 115 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pharmacology, Clinical Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Pomaglumetad Effects on Glutamate Biomarkers

NCT02919774
View directory record Official record
Conditions
Healthy Controls
Interventions
POMA, placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
4
States / cities
Birmingham, Alabama • Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 5, 2026, 6:21 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Soft Tissue Sarcoma

NCT00002492
View directory record Official record
Conditions
Sarcoma
Interventions
cisplatin, doxorubicin hydrochloride, isolated limb perfusion, conventional surgery, brachytherapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2000
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 5, 2026, 6:21 PM EDT
Terminated Phase 4 Interventional Results available

Clinical, Pharmacological and Molecular Effects of IV and Oral Acetaminophen in Adults With aSAH

NCT02549716
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Stroke
Interventions
IV acetaminophen, Oral acetaminophen, Oral placebo, IV placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 5, 2026, 6:21 PM EDT
Active, not recruiting Early Phase 1 Interventional

Proof-of-Concept Clinical Pharmacology Trial for HIV Antigen Presentation Therapeutic Biologic Mix

NCT07182838
View directory record Official record
Conditions
HIV Infections
Interventions
HIV Therapeutic Biologic Mix - HIV GP160 plus BCG Vaccine Mix for percutaneous use
Biological
Lead sponsor
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Industry
Eligibility
24 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 5, 2026, 6:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 QT Study in Healthy Male Subjects

NCT01986894
View directory record Official record
Conditions
Clinical Pharmacology, Healthy Volunteer Study
Interventions
Placebo, Pomalidomide, Moxifloxacin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 5, 2026, 6:21 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Computerized Cognitive Training in Young Adults With Depression

NCT03869463
View directory record Official record
Conditions
Depressive Symptoms
Interventions
Computerized Cognitive Training, Control
Other
Lead sponsor
Queens College, The City University of New York
Other
Eligibility
18 Years to 29 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Oct 5, 2026, 6:21 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration

NCT05999383
View directory record Official record
Conditions
THC, Cannabis, Cannabis Use, Cannabis Smoking, Tobacco Use, Vaping
Interventions
Cannabis, Nicotine, Pax Loose Leaf Vaporizer, Placebo Marijuana
Drug · Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 5, 2026, 6:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Metabolism of Bioactive Dietary Polyphenol Preparation (BDPP)

NCT04421079
View directory record Official record
Conditions
Healthy Control
Interventions
Trans-resveratrol, Concord grape juice, Grape seed polyphenol extract, Placebo
Dietary Supplement · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 5, 2026, 6:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Bioavailability of a Single Oral Dose of the Acetylsalicylic Acid Containing Dry Powder 500 mg in Comparison to the Bioavailability of a Single Oral Dose of Aspirin Tablets and Aspirin Effervescent Tablets in Healthy Adults.

NCT02394093
View directory record Official record
Conditions
Pharmacology, Clinical
Interventions
Aspirin (Acetylsalicylic acid, BAYe4465)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 19, 2016 · Synced Oct 5, 2026, 6:21 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Gender and HIV Infection on Zidovudine and Lamivudine Pharmacokinetics

NCT01386970
View directory record Official record
Conditions
HIV
Interventions
zidovudine 300mg and lamivudine 150mg as Combivir
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Oct 5, 2026, 6:21 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation

NCT07058974
View directory record Official record
Conditions
Smokers, Former Smokers
Interventions
lamivudine, rapamycin, Exercise Regimen, Spermidine
Drug · Behavioral · Dietary Supplement
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
60 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 5, 2026, 6:21 PM EDT
Completed Phase 2 Interventional Results available

Comparison of A Single Dose Combination of Methadone and Morphine With Morphine Alone for Treating Post-operative Pain

NCT00142519
View directory record Official record
Conditions
Pain
Interventions
Methadone, methadone and morphine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 5, 2026, 6:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of AVL-292 Following Multiple Doses and the Effect of Food on the Single-dose Pharmacokinetics of AVL-292

NCT01692184
View directory record Official record
Conditions
Healthy
Interventions
50 mg AVL-292, 100 mg AVL-292, 200 mg AVL-292, 350 mg AVL-292, Placebo capsules
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 5, 2026, 6:21 PM EDT
Completed Not applicable Interventional

Artificial Intelligence in Depression - Medication Enhancement

NCT04655924
View directory record Official record
Conditions
Depression
Interventions
Clinical Decision Support System
Device
Lead sponsor
Aifred Health
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
West Haven, Connecticut • Miami, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 5, 2026, 6:21 PM EDT
Completed Phase 1 Interventional

Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer

NCT00134069
View directory record Official record
Conditions
Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
sorafenib tosylate, cetuximab, irinotecan hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Aurora, Colorado • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Oct 5, 2026, 6:21 PM EDT
Completed No phase listed Observational

The Treatment of Children and Adolescents With Treatment-Resistant Depression

NCT00029640
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 5, 2026, 6:21 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Dabrafenib in Subjects With Hepatic Impairment

NCT02873650
View directory record Official record
Conditions
Hepatic Impairment
Interventions
dabrafenib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
4
States / cities
Los Angeles, California • DeBary, Florida • Berlin, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 5, 2026, 6:21 PM EDT
Completed Phase 4 Interventional

Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome

NCT05657860
View directory record Official record
Conditions
Prader-Willi Syndrome, Aggression, Self-Injurious Behavior, Pathologic Processes, Behavioral Symptoms, Intellectual Disability, Neurobehavioral Manifestations, Neurologic Manifestations, Nervous System Diseases, Abnormalities, Multiple, Congenital Abnormalities, Chromosome Disorders, Genetic Diseases, Inborn, Obesity, Overnutrition, Nutrition Disorders, Antihypertensive Agents, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action, Physiological Effects of Drugs, Skin-Picking
Interventions
Guanfacine Extended Release, Placebo
Drug · Other
Lead sponsor
Maimonides Medical Center
Other
Eligibility
6 Years to 35 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 5, 2026, 6:21 PM EDT
Completed Phase 2 Interventional Results available

Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis

NCT01710046
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
(CP-6890,550) Tofacitinib, Placebo, (CP-690,550) Tofacitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
5
States / cities
Los Angeles, California • Tampa, Florida • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Oct 5, 2026, 6:21 PM EDT
Completed Phase 3 Interventional Results available

Individualized Obesity Pharmacotherapy

NCT03374956
View directory record Official record
Conditions
Obesity
Interventions
Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion, Phentermine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 5, 2026, 6:21 PM EDT
Completed Phase 1 Interventional

Pyroxamide in Treating Patients With Advanced Cancer

NCT00042900
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
pyroxamide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 5, 2026, 6:21 PM EDT
Completed Phase 4 Interventional

Effectiveness Study of Single Photon Emission Computed Tomography (SPECT) Versus Positron Emission Tomography (PET) Myocardial Perfusion Imaging

NCT00976053
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Myocardial perfusion imaging
Procedure
Lead sponsor
Aspire Foundation
Other
Eligibility
30 Years to 90 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Oct 5, 2026, 6:21 PM EDT
Completed Phase 2 Interventional Results available

Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent

NCT01681095
View directory record Official record
Conditions
Coronary Artery Disease, Myocardial Ischemia, Coronary Disease, Heart Diseases, Valvular Heart Disease
Interventions
Custodiol HTK, Cold Blood Cardioplegia
Drug
Lead sponsor
Marc Sakwa, MD
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 5, 2026, 6:21 PM EDT
Completed Phase 4 Interventional Results available

Extended-release Naltrexone and Care Management for Alcohol Dependent Frequent Emergency Department Users

NCT02445339
View directory record Official record
Conditions
Alcohol Dependence, Alcohol Use Disorder
Interventions
XR-NTX+CM (Extended-Release Naltrexone plus Care Management)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 5, 2026, 6:21 PM EDT